前收市價 | 1.8800 |
開市 | 1.8600 |
買盤 | 1.7000 x 100 |
賣出價 | 1.7600 x 300 |
今日波幅 | 1.7300 - 1.8600 |
52 週波幅 | 1.6200 - 5.7000 |
成交量 | |
平均成交量 | 325,850 |
市值 | 118.695M |
Beta 值 (5 年,每月) | -0.37 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.7500 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 14.69 |
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Vor Biopharma Inc (NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) in acute myeloid leukemia patients. The time for neutrophil engraftment in all five patients treated with trem-cel (10-11 days) was similar to unedited transplants. All patients achieved high levels of myeloid donor chimerism by day 28. After achieving timely neutrophil engraftment and platelet recovery, patient 2 experienced secondary graft failure coincident